Potent inhibition of anoxic depolarization by the sodium channel blocker dibucaine

Heather A. Douglas, Jennifer K. Callaway, Jeremy Sword, Sergei A. Kirov, R. David Andrew

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Recurring waves of peri-infarct depolarizations (PIDs) propagate across gray matter in the hours and days following stroke, expanding the primary site of injury. Ischemic epolarization (termed anoxic depolarization or AD in live brain slices) is PID-like but immediately arises in the more metabolically compromised ischemic core. This causes dramatic neuronal and astrocyte swelling and dendritic beading with spine loss within minutes, resulting in acute cell death. AD is evoked in rodent neocortical slices by suppressing the Na +/K + -ATPase pump with either oxygen/glucose deprivation (OGD) or exposure to ouabain. The process driving AD and PIDs remains poorly understood. Here we show that dibucaine is a potent drug inhibiting AD because of its high binding affinity to the Na + channel. Field recording reveals that, when superfused with ouabain (5 min), neocortical slices pretreated with 1 μM dibucaine for 45 min display either no AD or delayed AD onset compared with untreated controls. If ouabain exposure is extended to 10 min, 1 μM dibucaine is still able to delay AD onset by ~60%. Likewise, it delays OGD-evoked AD onset by ~54% but does not depress action potentials (APs) or evoked orthodromic field potentials. Increasing dibucaine to 10 M inhibits AP firing, gradually putting the slice into a stasis that inhibits AD onset but also renders the slice functionally quiescent. Two-photon microscopy reveals that 10 μM dibucaine pretreatment prevents or helps reverse ouabain-induced structural neuronal damage. Although the therapeutic range of dibucaine is quite narrow, dibucaine-like drugs could prove therapeutically useful in inhibiting PIDs and their resultant neuronal damage.

Original languageEnglish (US)
Pages (from-to)1482-1494
Number of pages13
JournalJournal of Neurophysiology
Volume105
Issue number4
DOIs
StatePublished - Apr 1 2011

Fingerprint

Dibucaine
Sodium Channel Blockers
Ouabain
Action Potentials
Oxygen
Glucose
Photons
Astrocytes
Pharmaceutical Preparations
Microscopy
Rodentia
Spine
Cell Death
Stroke
Wounds and Injuries
Brain

Keywords

  • Caine
  • Cortical spreading depression
  • Oxygen/glucose deprivation
  • Peri-infarct depolarization

ASJC Scopus subject areas

  • Neuroscience(all)
  • Physiology

Cite this

Potent inhibition of anoxic depolarization by the sodium channel blocker dibucaine. / Douglas, Heather A.; Callaway, Jennifer K.; Sword, Jeremy; Kirov, Sergei A.; Andrew, R. David.

In: Journal of Neurophysiology, Vol. 105, No. 4, 01.04.2011, p. 1482-1494.

Research output: Contribution to journalArticle

Douglas, Heather A. ; Callaway, Jennifer K. ; Sword, Jeremy ; Kirov, Sergei A. ; Andrew, R. David. / Potent inhibition of anoxic depolarization by the sodium channel blocker dibucaine. In: Journal of Neurophysiology. 2011 ; Vol. 105, No. 4. pp. 1482-1494.
@article{79751c8ea4d6418d938e1f90bcfd97c2,
title = "Potent inhibition of anoxic depolarization by the sodium channel blocker dibucaine",
abstract = "Recurring waves of peri-infarct depolarizations (PIDs) propagate across gray matter in the hours and days following stroke, expanding the primary site of injury. Ischemic epolarization (termed anoxic depolarization or AD in live brain slices) is PID-like but immediately arises in the more metabolically compromised ischemic core. This causes dramatic neuronal and astrocyte swelling and dendritic beading with spine loss within minutes, resulting in acute cell death. AD is evoked in rodent neocortical slices by suppressing the Na +/K + -ATPase pump with either oxygen/glucose deprivation (OGD) or exposure to ouabain. The process driving AD and PIDs remains poorly understood. Here we show that dibucaine is a potent drug inhibiting AD because of its high binding affinity to the Na + channel. Field recording reveals that, when superfused with ouabain (5 min), neocortical slices pretreated with 1 μM dibucaine for 45 min display either no AD or delayed AD onset compared with untreated controls. If ouabain exposure is extended to 10 min, 1 μM dibucaine is still able to delay AD onset by ~60{\%}. Likewise, it delays OGD-evoked AD onset by ~54{\%} but does not depress action potentials (APs) or evoked orthodromic field potentials. Increasing dibucaine to 10 M inhibits AP firing, gradually putting the slice into a stasis that inhibits AD onset but also renders the slice functionally quiescent. Two-photon microscopy reveals that 10 μM dibucaine pretreatment prevents or helps reverse ouabain-induced structural neuronal damage. Although the therapeutic range of dibucaine is quite narrow, dibucaine-like drugs could prove therapeutically useful in inhibiting PIDs and their resultant neuronal damage.",
keywords = "Caine, Cortical spreading depression, Oxygen/glucose deprivation, Peri-infarct depolarization",
author = "Douglas, {Heather A.} and Callaway, {Jennifer K.} and Jeremy Sword and Kirov, {Sergei A.} and Andrew, {R. David}",
year = "2011",
month = "4",
day = "1",
doi = "10.1152/jn.00817.2010",
language = "English (US)",
volume = "105",
pages = "1482--1494",
journal = "Journal of Neurophysiology",
issn = "0022-3077",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Potent inhibition of anoxic depolarization by the sodium channel blocker dibucaine

AU - Douglas, Heather A.

AU - Callaway, Jennifer K.

AU - Sword, Jeremy

AU - Kirov, Sergei A.

AU - Andrew, R. David

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Recurring waves of peri-infarct depolarizations (PIDs) propagate across gray matter in the hours and days following stroke, expanding the primary site of injury. Ischemic epolarization (termed anoxic depolarization or AD in live brain slices) is PID-like but immediately arises in the more metabolically compromised ischemic core. This causes dramatic neuronal and astrocyte swelling and dendritic beading with spine loss within minutes, resulting in acute cell death. AD is evoked in rodent neocortical slices by suppressing the Na +/K + -ATPase pump with either oxygen/glucose deprivation (OGD) or exposure to ouabain. The process driving AD and PIDs remains poorly understood. Here we show that dibucaine is a potent drug inhibiting AD because of its high binding affinity to the Na + channel. Field recording reveals that, when superfused with ouabain (5 min), neocortical slices pretreated with 1 μM dibucaine for 45 min display either no AD or delayed AD onset compared with untreated controls. If ouabain exposure is extended to 10 min, 1 μM dibucaine is still able to delay AD onset by ~60%. Likewise, it delays OGD-evoked AD onset by ~54% but does not depress action potentials (APs) or evoked orthodromic field potentials. Increasing dibucaine to 10 M inhibits AP firing, gradually putting the slice into a stasis that inhibits AD onset but also renders the slice functionally quiescent. Two-photon microscopy reveals that 10 μM dibucaine pretreatment prevents or helps reverse ouabain-induced structural neuronal damage. Although the therapeutic range of dibucaine is quite narrow, dibucaine-like drugs could prove therapeutically useful in inhibiting PIDs and their resultant neuronal damage.

AB - Recurring waves of peri-infarct depolarizations (PIDs) propagate across gray matter in the hours and days following stroke, expanding the primary site of injury. Ischemic epolarization (termed anoxic depolarization or AD in live brain slices) is PID-like but immediately arises in the more metabolically compromised ischemic core. This causes dramatic neuronal and astrocyte swelling and dendritic beading with spine loss within minutes, resulting in acute cell death. AD is evoked in rodent neocortical slices by suppressing the Na +/K + -ATPase pump with either oxygen/glucose deprivation (OGD) or exposure to ouabain. The process driving AD and PIDs remains poorly understood. Here we show that dibucaine is a potent drug inhibiting AD because of its high binding affinity to the Na + channel. Field recording reveals that, when superfused with ouabain (5 min), neocortical slices pretreated with 1 μM dibucaine for 45 min display either no AD or delayed AD onset compared with untreated controls. If ouabain exposure is extended to 10 min, 1 μM dibucaine is still able to delay AD onset by ~60%. Likewise, it delays OGD-evoked AD onset by ~54% but does not depress action potentials (APs) or evoked orthodromic field potentials. Increasing dibucaine to 10 M inhibits AP firing, gradually putting the slice into a stasis that inhibits AD onset but also renders the slice functionally quiescent. Two-photon microscopy reveals that 10 μM dibucaine pretreatment prevents or helps reverse ouabain-induced structural neuronal damage. Although the therapeutic range of dibucaine is quite narrow, dibucaine-like drugs could prove therapeutically useful in inhibiting PIDs and their resultant neuronal damage.

KW - Caine

KW - Cortical spreading depression

KW - Oxygen/glucose deprivation

KW - Peri-infarct depolarization

UR - http://www.scopus.com/inward/record.url?scp=79955142391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955142391&partnerID=8YFLogxK

U2 - 10.1152/jn.00817.2010

DO - 10.1152/jn.00817.2010

M3 - Article

C2 - 21273307

AN - SCOPUS:79955142391

VL - 105

SP - 1482

EP - 1494

JO - Journal of Neurophysiology

JF - Journal of Neurophysiology

SN - 0022-3077

IS - 4

ER -